Biotechnology Value Fund — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in
BoardAlexandra Cantley(Director)inSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in
Co-investorsMPM BioImpactPfizer Venture InvestmentsMirae Asset Venture InvestmentPfizer VenturesPolaris PartnersTaiho Ventures, LLC
Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers.
BiotechDeep TechHealthtechSouth San Francisco, US
Cameron Pitt(Executive Officer, Director)Ying Huang(Director)Derek Metzger(Executive Officer)
BoardMaha Katabi(Director)Perry Nisen(Executive Officer, Director)Maria Fardis(Director)
Co-investorsLongitude CapitalSofinnova VenturesVida VenturesFrazier Life Sciences
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.